Galectin-3 and S100A9: Novel diabetogenic factors mediating pancreatic cancer-associated diabetes
Diabetes Care Jul 05, 2019
Liao WC, et al. - In this investigation, researchers identified pancreatic cancer-associated diabetes (PCDM) mediators and assessed their utility in differentiating PCDM from type 2 diabetes. Secreted proteins of MIA PaCa-2 cells were recognized by proteomics, and those with ≥10-fold overexpression in transcriptome analysis were evaluated by bioinformatics and glucose uptake assay to identify candidate factors. In PCDM tumors, galectin-3 and S100A9 are overexpressed and mediate insulin resistance. In subjects with new-onset diabetes, galectin-3 and S100A9 distinguish PCDM from type 2 diabetes.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries